Bristol-Myers Squibb Co
(LTS:0R1F)
$
59.4
-0.61 (-1.02%)
Market Cap: 119.70 Bil
Enterprise Value: 163.01 Bil
PE Ratio: 0
PB Ratio: 6.98
GF Score: 82/100 Bristol-Myers Squibb Co at Leerink Partners Global Biopharma Conference Transcript
Mar 13, 2024 / 02:00PM GMT
Release Date Price:
$54.1
(-0.73%)
David Reed Risinger
Leerink Partners LLC, Research Division - Senior MD & Senior Research Analyst
Great. So good morning, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners, and it's very much my pleasure to welcome Bristol-Myers' Chief Medical Officer, Samit Hirawat. And with him in the audience are Tim Power and Janet Barth in Investor Relations. We appreciate Samit joining us, taking the time out of his busy schedule to be with us here today.
Questions & Answers
David Reed Risinger
Leerink Partners LLC, Research Division - Senior MD & Senior Research Analyst
So I guess it'd be great to have you kick off just by framing your vision for Bristol R&D, including some of the company's most substantial R&D projects that we should be focused on. And I know there are a lot of them. But it'd be great to have you just provide an initial framework.
Samit Hirawat
Bristol-Myers Squibb Company - Executive VP & Chief Medical Officer of Drug Development
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot